Publications by authors named "Pierre Brunel"

Claim this Profile
C
Clinical consequences of varenicline shortage: A study on the French national pharmacovigilance database.
Amélie Lepert, Delphine Bourneau-Martin, Bénédicte Lebrun-Vignes, Alexandra Gentil, Pierre Brunel

Therapie· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive perioperative blood management in patients undergoing elective bypass cardiac surgery: Benefit effect of health care education and systematic correction of iron deficiency and anemia on red blood cell transfusion.
Hélène Charbonneau, Stéphanie Savy, Nicolas Savy, Marie Pasquié, Nicolas Mayeur, Pierre Brunel

J Clin Anesth· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Induced Uveitis Related to Checkpoint Inhibitors and MAP-kinase Inhibitors.
Thomas Thibault, Inès Ben Ghezala, Romane Freppel, Abdessamad Rajillah, Charlène Boulay, Pierre Brunel

Ophthalmology· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient blood management in elective bypass cardiac surgery: A 2-step single-centre interventional trial to analyse the impact of an educational programme and erythropoiesis stimulation on red blood cell transfusion.
Hélène Charbonneau, Marie Pasquié, Pierre Berthoumieu, Nicolas Savy, Gérard Autones, Pierre Brunel

Contemp Clin Trials Commun· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study.
Alain Attar, Gérard Duru, Xavier Roblin, Bernard Savarieau, Pierre Brunel

Dig Liver Dis· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab.
Xavier Roblin, Alain Attar, Michel Lamure, Bernard Savarieau, Pierre Brunel

J Mark Access Health Policy· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis